Gabelli Funds’s Crinetics Pharmaceuticals CRNX Stock Holding History

Gabelli Funds’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,000	Closed	-$218K	–	1300
2026 Q1	$218K	Buy	+6,000	New	+$268K	﹤0.01%	1153

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gabelli Funds's CRNX Position: Q2 2026 in Review

Gabelli Funds sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 6,000 shares — an estimated $218K sold.

Gabelli Funds first reported a position in CRNX in Q1 2026 and held it in 1 quarter. The position peaked at $218K in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Gabelli Funds reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Gabelli Funds sold 6,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $218K.
Gabelli Funds first reported a position in Crinetics Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Gabelli Funds's Crinetics Pharmaceuticals position peaked at $218K in Q1 2026.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.